🍄 #52 - Charley Wininger - Will we have couples therapy on MDMA?


Hi guys we are back!

And today I talk to Charley Wininger. He is a licensed Psychoanalyst and Mental Health Counselor for individuals and couples. Charley is an author and an expert on Psychedelic Drugs, the 71-year-old is also a relationship counselor who calls MDMA the “relationship superglue” and just published the book called. “Listening to ecstasy

When reading about Charley’s book, I was wondering: is our connection on a neural level the most important one? Charley must know. In his book he talks about his “MDMA” journey with his wife Shelley, since the two of them, you could say, became relationship scientists with the support of ecstasy.

Since the ideas of marriage and relationships have changed big time and we seem to need new tools to understand each other’s minds and hearts. Charley and I talk about the rediscovery of MDMA in the context of the psychedelic renaissance. And how MDMA could supports couples therapy in the future and what that would mean for love.

Enjoy the episode!

More news and info for you to come this week!


I am excited about this conference about Ibogaine since the substance is becoming more and more researched in terms of healing heroin and alcohol addiction. Ibogaine is a naturally occurring psychoactive substance found in plants in the Apocynaceae family such as Tabernanthe iboga, Voacanga africana, and Tabernaemontana undulata. It is a psychedelic with dissociative properties. Preliminary research indicates that it may help counter drug addiction.

I am moderating the panel “Ibogaine medicalization: the role of capital markets” on Friday 19th February at 6 pm EST or midnight at Central European time.

Soooo this is our little present for you if you want to join us.

Get our nice discount, just for you!

The online conference will take place on 19th - 20th February 2021.  Get 20% off your tickets now

Code: AnneP20

Get tickets


The #IbogaineConference: A Molecular Masterclass, a two-day virtual conference will take place on 19th - 20th February 2021, from 8:45 am EST. The event is presented by Universal Ibogaine, a leading company in the field, by MICRODOSE PSYCHEDELIC INSIGHTS and The Conscious Fund, a leading VC and Investor Firm in the field.

(@IbogaineInc @MicrodoseHQ @ConsciousFundHQ)


Join over 50 of the leading researchers in the therapeutic use of Ibogaine, a powerful psychedelic plant from Africa showing immense potential in the treatment of addiction.

Ibogaine Expert Deborah Mash, who was on our show already, will be speaking too! Here is the episode with her if you need a refresher:

Listen on Apple Podcasts

Wait, there is more! 

Enjoy further input on Stanislav Grof, our incredible guest from last time..

Find the link to the “Shift Network”  (www.theshiftnetwork.com) where you can take a look at Stan’s courses on

- Psychology of the Future

- The Way of the Psychonaut

- Psyche and Cosmos ( with Rick Tarnas)

And please join The Open Center for “The Psychedelic Renaissance: Past, Present and Future” with lots of our favorite people in the psychedelic world!  

Paul Stamets; Anthony Bossis, Ph.D.; Rick Doblin, Ph.D.; Brian Muraresku; Mark Plotkin, Ph.D.; Michael Mithoefer, M.D.; Annie Mithoefer, B.S.M.; Bill Richards, Ph.D. and Albert Garcia-Romeu, Ph.D. are part of the online series…

When & Where?

February 22nd - March 29th

Virtual Event, View the full schedule via this link.

View Schedule


A six-week series that will bring together the world’s leading experts from the scientific, medical, and research fields for an in-depth and dynamic presentation that will explore the past, present, and future of psychedelic research. This unique series of evening presentations will address the history of psychedelics from classical antiquity and among Amazonian shamans through current research investigating the therapeutic value of psilocybin, MDMA, and other compounds for clinical applications including PTSD, addiction, existential distress in palliative care, and clinical depression. Implications for the utilization of these novel therapies for the future of healthcare will be addressed.